
Conference Coverage
Latest News

Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation

Integrating Nutrition and Lifestyle Strategies in Pediatric Multiple Sclerosis Management

MDS Congress 2025: Top Expert Interviews and Key Takeaways

Earlier Initiation of Pimavanserin Leads to Better Improvement of Parkinson Disease Psychosis Symptoms

Trappsol Cyclo Shows Promising Results in Newborns With Niemann-Pick Disease Type C1

Shorts










Videos
Podcasts
Continuing Medical Education
All News

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society (STARS) discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

David Stamler, MD, chief executive officer at Alterity Therapeutics, gave clinical perspectives on ATH434, an emerging agent showing promise in phase 2 studies of multiple system atrophy.

A recent review of studies over the past decade, presented at CNS 2025, suggests that the ketogenic diet can significantly reduce seizure frequency in children with drug-resistant epilepsy.

A new study reported that children and adolescents with Tourette syndrome on dopamine D2 receptor antagonists had higher rates of psychiatric and metabolic adverse events than those unexposed.

Beth McQuiston, MD, neurologist and medical director in Abbott’s diagnostics business, discussed the clinical value of Abbott’s FDA-cleared i-STAT TBI test as it was named to TIME’S 2025 Best Inventions List.

Leigh Charvet, PhD, professor of neurology at NYU Grossman School of Medicine, provided clinical insights to her team’s pilot study using at-home brain stimulation to reduce cannabis use in women with multiple sclerosis.

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

Researchers recently received a $2.8 million 3-year grant to develop next-generation implantable responsive neurostimulation devices for patients with epilepsy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on deep brain stimulation for Parkinson disease.

An interim analysis from TEMPO-4, presented as a late-breaker at MDS 2025, showed that tavapadon showed sustained long-term safety in Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 17, 2025.

A phase 3 trial presented at the 2025 MDS Congress suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

The co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.

A phase 2 study presented at 2025 MDS revealed that onabotulinumtoxinA significantly improved tremor-related disability compared with placebo in patients with upper limb essential tremor.